Spotting pancreatic cancer early

Date:

02/05/2016

The Immpact project, which focuses on the final stages of the development of the new blood test, was launched in June 2015 for a duration of two years. It is implemented by Swedish start-up Immunovia. “The objective is to carry out the studies and commercialisation activities that are needed to take our invention from a prototype to a test that is available to the public,” says CEO Mats Grahn.

Read more

Pancreatic cancer is usually detected too late, leaving patients little hope of recovery. But this may be about to change. A Swedish SME has developed a blood test to help clinicians identify new cases earlier, and it intends to make this diagnostic capability available very soon. Clinical validation is under way in an EU-funded project.

<p>Contact</p>

Author

Anonymous (not verified)

Xtranet-ISA